Quince Therapeutics Q2 2024 Earnings Report

Quince Therapeutics EPS Results

• Actual EPS: -$0.18
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Quince Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Quince Therapeutics Announcement Details

• Quarter: Q2 2024
• Date: 8/13/2024
• Time: N/A
• Conference Call Date: Monday, August 12, 2024
• Conference Call Time: 6:00PM ET

Quince Therapeutics (NASDAQ:QNCX) (NASDAQ:QNCX) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel small-molecule therapies for neurological and psychiatric disorders. Founded in 2023 as a spin-out from H. Lundbeck, Quince leverages decades of neuroscience research to advance a diversified pipeline of assets targeting central nervous system function. The company is headquartered in Cambridge, Massachusetts, with additional research and development capabilities in Europe.

The company’s lead programs encompass multiple mechanisms of action aimed at addressing unmet medical needs in conditions such as attention-deficit/hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), chronic pain and epilepsy. Quince’s discovery engine focuses on identifying compounds that modulate neurotransmitter transporters, ion channels and receptor systems integral to neuronal signaling. Its most advanced candidates include a dopamine reuptake modulator for ADHD, a Kv7 channel activator for seizure control and a novel receptor antagonist for stress-related disorders.

Since its inception, Quince Therapeutics has assembled a seasoned leadership team drawn from the biopharma and academic neuroscience communities. Chief Executive Officer Bill Regitz, who previously held executive roles in neuroscience research organizations, leads the company’s strategic direction and operations. The executive team is supported by a board of directors and scientific advisors with deep expertise in translational research, clinical development and regulatory affairs.

Quince maintains a global development strategy, conducting clinical studies across North America and Europe and pursuing collaborative partnerships to extend its reach into emerging markets. With a focus on rigorous proof-of-concept trials and a clear path to commercialization, Quince aims to deliver first-in-class therapies that improve patient outcomes and address significant gaps in the treatment of central nervous system diseases.